Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2020

View Archived Issues

Enrollment ongoing in phase I/II study of oral BDTX-189 in advanced solid tumors

Sanofi initiates phase III study of SAR-408701 in CEACAM5-positive metastatic nonsquamous NSCLC

Novel muraminomicin derivatives with potent activity in MRSA infection models

OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML

ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy

Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors

Roche discloses new EGFR mutant inhibitors

B cells help T cells succeed during checkpoint blockade

Single transcription factor enables chronic toxoplasma infection

AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators

Meiji Seika Pharma describes new PDE4 inhibitors

New compounds for Huntington's disease presented by PTC Therapeutics

Pfizer begins phase III study of PF-06801591 in high-risk nonmuscle invasive bladder cancer

Xalud starts phase II study of XT-150 for pain due to knee osteoarthritis

SUMOylation inhibition enhances targeting of farnesoid X receptor for liver fibrosis

Kadmon discloses new SLC2A3 inhibitors

Oncogene Ras affects memory consolidation

Phase III study of surufatinib in pancreatic neuroendocrine tumors stopped early for efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...